test application
breakthrough test
finger prick blood test
o Dissemination of METAglut1
METAdiag platform
market launch
o Extension
o Downsizing
Europe big
market access
IVD market
years
METAglut1 test’s positive results
essential nutrient transporters
big data
actionable results
disruptive blood
Diagnostic platform
early diagnosis
leading Medical Testing Laboratory
commercial launch
METAdiag monitors cells’ energetic needs thanks
leading scientific journal
medical unmet need
abnormal cellular energetics METAFORA
large scale validation study
proprietary biomarkers
children
curable neuro-metabolic disease
debilitating
CERBA Healthcare
North America
Receptor Binding Domains
business development effort
Italy
Spain
UK
RBDs
vitamins
Germany
countries
France
amino acids
Artificial Intelligence
physicians
therapeutic monitoring of cancers
GLUT1 Deficiency Syndrome
routine clinical practice
partnering agreement
serious diseases
newborn screening
glucose
key player
Phase
cell’s surface
edge algorithms
basis
USA
project ends
ambitions
commercialization
reimbursement
cumulative revenues